Ontology type: schema:ScholarlyArticle
2021-09-06
AUTHORSAkihiko Izumi, Takayoshi Tachibana, Taiki Ando, Masatsugu Tanaka, Heiwa Kanamori, Hideaki Nakajima
ABSTRACTThis single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD. More... »
PAGES69-76
http://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4
DOIhttp://dx.doi.org/10.1007/s12185-021-03217-4
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1140912417
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34490598
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease-Free Survival",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hematopoietic Stem Cell Transplantation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hepatic Veno-Occlusive Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Inotuzumab Ozogamicin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Recurrence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Salvage Therapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Transplantation, Homologous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Izumi",
"givenName": "Akihiko",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Tachibana",
"givenName": "Takayoshi",
"id": "sg:person.01074653417.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Ando",
"givenName": "Taiki",
"id": "sg:person.010621551621.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010621551621.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Tanaka",
"givenName": "Masatsugu",
"id": "sg:person.01171141246.33",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.414944.8",
"name": [
"Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Kanamori",
"givenName": "Heiwa",
"id": "sg:person.01060176576.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Nakajima",
"givenName": "Hideaki",
"id": "sg:person.010061552415.35",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061552415.35"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.leu.2402922",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052214299",
"https://doi.org/10.1038/sj.leu.2402922"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s12185-019-02749-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1122120596",
"https://doi.org/10.1007/s12185-019-02749-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bmt.2016.130",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017627248",
"https://doi.org/10.1038/bmt.2016.130"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2011.351",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050351263",
"https://doi.org/10.1038/leu.2011.351"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bmt.2015.52",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003530776",
"https://doi.org/10.1038/bmt.2015.52"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/978-1-60761-629-0_13",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023260237",
"https://doi.org/10.1007/978-1-60761-629-0_13"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-09-06",
"datePublishedReg": "2021-09-06",
"description": "This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27\u00a0years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1\u00a0year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD.",
"genre": "article",
"id": "sg:pub.10.1007/s12185-021-03217-4",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1076985",
"issn": [
"0925-5710",
"1865-3774"
],
"name": "International Journal of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "115"
}
],
"keywords": [
"hematopoietic cell transplantation",
"veno-occlusive disease",
"allogeneic hematopoietic cell transplantation",
"acute lymphoblastic leukemia",
"inotuzumab ozogamicin",
"cell transplantation",
"lymphoblastic leukemia",
"progression-free survival rates",
"single-center retrospective study",
"negative minimal residual disease",
"post-HCT complications",
"complete hematological remission",
"minimal residual disease",
"salvage therapy",
"salvage chemotherapy",
"evaluable patients",
"maintenance therapy",
"disease remission",
"hematological remission",
"consecutive patients",
"case series",
"retrospective study",
"residual disease",
"favorable outcome",
"patients",
"eligibility criteria",
"survival rate",
"ozogamicin",
"remission",
"transplantation",
"therapy",
"leukemia",
"high rate",
"disease",
"further investigation",
"comprehensive treatment",
"iNO",
"chemotherapy",
"complications",
"death",
"outcomes",
"treatment",
"study",
"rate",
"years",
"criteria",
"investigation",
"series",
"cycle"
],
"name": "A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation",
"pagination": "69-76",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1140912417"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12185-021-03217-4"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34490598"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12185-021-03217-4",
"https://app.dimensions.ai/details/publication/pub.1140912417"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:38",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_914.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12185-021-03217-4"
}
]Download the RDF metadata as:Â json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-021-03217-4'
This table displays all metadata directly associated to this object as RDF triples.
244 TRIPLES
22 PREDICATES
99 URIs
85 LITERALS
25 BLANK NODES